Gilead's lenacapavir reduced HIV infections by 96% in trial

A pharmacist holds a bottle of lenacapavir, the new injectable drug for HIV prevention. Nardus Engelbrecht | AP GileadPfizer's twice-yearly…

Eli Lilly could become the first $1 trillion healthcare stock

A sign with the company logo is displayed outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, on…